1: Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab. 2001 Mar;86(3):972-9.

2: Morrione A. Grb10 proteins in insulin-like growth factor and insulin receptor signaling(review). Int J Mol Med. 2000 Feb;5(2):151-4.

3: Andersen O. Insulin receptor binding and glucose metabolism in normal human pregnancy and gestational diabetes mellitus. A review. Dan Med Bull. 1990 Dec;37(6):492-501.

4: Pedersen O. Insulin receptor- and nonreceptor-controlled cellular substrate processing. A review of clinical studies in the isolated human adipocyte model. J Endocrinol Invest. 1985 Feb;8(1):77-87.

5: Etherton TD. The role of insulin-receptor interactions in regulation of nutrient utilization by skeletal muscle and adipose tissue: a review. J Anim Sci. 1982 Jan;54(1):58-67.

1: Mills PJ, Ziegler MG, Rehman J, Maisel AS. Catecholamines, catecholamine receptors, cell adhesion molecules, and acute stressor-related changes in cellular immunity. Adv Pharmacol. 1998;42:587-90.

2: Goldstein DS. Catecholamine receptors and signal transduction. Overview. Adv Pharmacol. 1998;42:379-90.

3: Caron MG, Lefkowitz RJ. Catecholamine receptors: structure, function, and regulation. Recent Prog Horm Res. 1993;48:277-90.

4: Strosberg AD. Structure-function analysis of the three beta-adrenergic catecholamine receptors. Psychopharmacol Ser. 1993;10:9-14.

5: Brodde OE. Physiology and pharmacology of cardiovascular catecholamine receptors: implications for treatment of chronic heart failure. Am Heart J. 1990 Dec;120(6 Pt 2):1565-72.

6: O'Dowd BF, Nguyen T, Tirpak A, Jarvie KR, Israel Y, Seeman P, Niznik HB. Cloning of two additional catecholamine receptors from rat brain. FEBS Lett. 1990 Mar 12;262(1):8-12.

7: Hiemke C, Banger M, Ghraf R, Knuppen R.Do catecholestrogens interact with the in vitro binding of radioligands to catecholamine receptors? J Steroid Biochem. 1983 Oct;19(4):1469-74.

8: Cools AR, Oosterloo SK. (3,4-Dihydroxyphenylimino)-2-imidazoline (DPI) and its action at noradrenergic and dopaminergic receptors in the nucleus accumbens of rats: mesolimbic catecholamine receptors and hyperactivity. J Neural Transm Suppl. 1983;18:181-8.

9: Helmeste DM, Seeman P, Coscina DV. Relation between brain catecholamine receptors and dopaminergic stereotypy in rat strains. Eur J Pharmacol. 1981 Feb 19;69(4):465-70.

10: Reisine T. Adaptive changes in catecholamine receptors in the central nervous system. Neuroscience. 1981;6(8):1471-502.

11: Titeler M, Seeman P. Ergot and catecholamine potencies at catecholamine receptors. Adv Biochem Psychopharmacol. 1980;23:35-40.

1: Sigal RJ, Fisher SJ, Manzon A, Morais JA, Halter JB, Vranic M, Marliss EB. Glucoregulation during and after intense exercise: effects of alpha-adrenergic blockade. Metabolism. 2000 Mar;49(3):386-94.

2: Wang JS, Cheng LJ. Effect of strenuous, acute exercise on alpha2-adrenergic agonist-potentiated platelet activation. Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1559-65.

3: White CM. Catecholamines and their blockade in congestive heart failure. Am J Health Syst Pharm. 1998 Apr 1;55(7):676-82.

4: Esforzado Armengol N, Cases Amenos A, Bono Illa M, Gaya Bertran J, Calls Minesta J, Rivera Fillat F. Autonomic nervous system and adrenergic receptors in chronic hypotensive haemodialysis patients. Nephrol Dial Transplant. 1997 May;12(5):939-44.

5: Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther. 1996 Apr;59(4):450-7.

6: Murray DR, Irwin M, Rearden CA, Ziegler M, Motulsky H, Maisel AS. Sympathetic and immune interactions during dynamic exercise. Mediation via a beta 2-adrenergic-dependent mechanism. Circulation. 1992 Jul;86(1):203-13.

7: Anwar A, Kohn SR, Dunn JF, Hymer TK, Kennedy GT, Crawford MH, O'Rourke RA, Katz MS. Altered beta adrenergic receptor function in subjects with symptomatic mitral valve prolapse. Am J Med Sci. 1991 Aug;302(2):89-97.

8: Leier CV, Binkley PF, Cody RJ. Alpha-adrenergic component of the sympathetic nervous system in congestive heart failure. Circulation. 1990 Aug;82(2 Suppl):I68-76.

9: Lonnqvist F, Nyberg B, Wahrenberg H, Arner P. Catecholamine-induced lipolysis in adipose tissue of the elderly. J Clin Invest. 1990 May;85(5):1614-21.

10: Karliner JS. Effects of beta-blockade on beta-adrenergic receptors and signal transduction. J Cardiovasc Pharmacol. 1989;14 Suppl 5:S6-12.

11: Laustiola KE, Lassila R, Kaprio J, Koskenvuo M. Decreased beta-adrenergic receptor density and catecholamine response in male cigarette smokers. A study of monozygotic twin pairs discordant for smoking. Circulation. 1988 Nov;78(5 Pt 1):1234-40.

12: Boudoulas H, Wooley CF. Mitral valve prolapse syndrome: neuro-endocrinological aspects. Herz. 1988 Aug;13(4):249-58.

13: Mannelli M, Pupilli C, Fabbri G, Musante R, De Feo ML, Franchi F, Giusti G. Endogenous dopamine (DA) and DA2 receptors: a mechanism limiting excessive sympathetic-adrenal discharge in humans. J Clin Endocrinol Metab. 1988 Mar;66(3):626-31.

14: Burman KD, Ferguson EW, Djuh YY, Wartofsky L, Latham K. Beta receptors in peripheral mononuclear cells increase acutely during exercise. Acta Endocrinol (Copenh). 1985 Aug;109(4):563-8.

15: Williams RS. Role of receptor mechanisms in the adaptive response to habitual exercise. Am J Cardiol. 1985 Apr 26;55(10):68D-73D.

16: Kelly JG. Choice of selective versus nonselective beta blockers: implications for exercise training. Am J Cardiol. 1985 Apr 26;55(10):162D-166D.

17: Williams ME, Gervino EV, Rosa RM, Landsberg L, Young JB, Silva P, Epstein FH. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med. 1985 Mar 28;312(13):823-7.

18: Pequignot JM, Guell A, Gauquelin G, Jarsaillon E, Annat G, Bes A, Peyrin L, Gharib C. Epinephrine, norepinephrine, and dopamine during a 4-day head-down bed rest. J Appl Physiol. 1985 Jan;58(1):157-63.

19: Lehmann M, Schmid P, Keul J. Age- and exercise-related sympathetic activity in untrained volunteers, trained athletes and patients with impaired left-ventricular contractility. Eur Heart J. 1984 Nov;5 Suppl E:1-7.

20: Franz IW, Lohmann FW, Koch G, Quabbe HJ. Aspects of hormonal regulation of lipolysis during exercise: effects of chronic beta-receptor blockade. Int J Sports Med. 1983 Feb;4(1):14-20.

21: Borst C, Wieling W, van Brederode JF, Hond A, de Rijk LG, Dunning AJ. Mechanisms of initial heart rate response to postural change. Am J Physiol. 1982 Nov;243(5):H676-81.

1: Svoboda M, Portois L, Malaisse WJ. Glucose regulation of the expression of the glucagon receptor gene. Mol Genet Metab. 1999 Oct;68(2):258-67.

2: Ngan ES, Chow LS, Tse DL, Du X, Wei Y, Mojsov S, Chow BK. Functional studies of a glucagon receptor isolated from frog Rana tigrina rugulosa: implications on the molecular evolution of glucagon receptors in vertebrates. FEBS Lett. 1999 Sep 3;457(3):499-504.

3: de Laszlo SE, Hacker C, Li B, Kim D, MacCoss M, Mantlo N, Pivnichny JV, Colwell L, Koch GE, Cascieri MA, Hagmann WK. Potent, orally absorbed glucagon receptor antagonists. Bioorg Med Chem Lett. 1999 Mar 8;9(5):641-6.

4: Morris BJ, Jeyasingam CL, Zhang W, Curtain RP, Griffiths LR. Influence of family history on frequency of glucagon receptor Gly40Ser mutation in hypertensive subjects. Hypertension. 1997 Dec;30(6):1640-1.

5: Buggy JJ, Heurich RO, MacDougall M, Kelley KA, Livingston JN, Yoo-Warren H, Rossomando AJ. Role of the glucagon receptor COOH-terminal domain in glucagon-mediated signaling and receptor internalization. Diabetes. 1997 Sep;46(9):1400-5.

6: Chicchi GG, Graziano MP, Koch G, Hey P, Sullivan K, Vicario PP, Cascieri MA. Alterations in receptor activation and divalent cation activation of agonist binding by deletion of intracellular domains of the glucagon receptor. J Biol Chem. 1997 Mar 21;272(12):7765-9.

7: Burcelin R, Katz EB, Charron MJ. Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. Diabetes Metab. 1996 Dec;22(6):373-96.

8: Morris BJ, Chambers SM. Hypothesis: glucagon receptor glycine to serine missense mutation contributes to one in 20 cases of essential hypertension. Clin Exp Pharmacol Physiol. 1996 Dec;23(12):1035-7.

9: Hansen LH, Abrahamsen N, Hager J, Jelinek L, Kindsvogel W, Froguel P, Nishimura E. The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon. Diabetes. 1996 Jun;45(6):725-30.

10: Buggy J, Rossomando A, MacDougall M, Mierz D, Wunderlich D, Yoo-Warren H. Human glucagon receptor monoclonal antibodies: antagonism of glucagon action and use in receptor characterization. Horm Metab Res. 1996 May;28(5):215-9.

11: Heurich RO, Buggy JJ, Vandenberg MT, Rossomando AJ. Glucagon induces a rapid and sustained phosphorylation of the human glucagon receptor in Chinese hamster ovary cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):905-10.

12: Jaksch M, Hofmann S, Gerbitz KD. Glucagon receptor gene mutation in NIDDM. Diabetologia. 1996 Feb;39(2):248.

13: Gough SC, Saker PJ, Pritchard LE, Merriman TR, Merriman ME, Rowe BR, Kumar S, Aitman T, Barnett AH, Turner RC, et al. Mutation of the glucagon receptor gene and diabetes mellitus in the UK: association or founder effect? Hum Mol Genet. 1995 Sep;4(9):1609-12.

14: Buggy J, Hull J, Yoo-Warren H. Isolation and structural analysis of the 5' flanking region of the gene encoding the human glucagon receptor. Biochem Biophys Res Commun. 1995 Mar 8;208(1):339-44.

15: Hager J, Hansen L, Vaisse C, Vionnet N, Philippi A, Poller W, Velho G, Carcassi C, Contu L, Julier C, et al. A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus. Nat Genet. 1995 Mar;9(3):299-304.

16: Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, Rosenberg GB, et al. The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene. 1994 Mar 25;140(2):203-9.

17: MacNeil DJ, Occi JL, Hey PJ, Strader CD, Graziano MP. Cloning and expression of a human glucagon receptor. Biochem Biophys Res Commun. 1994 Jan 14;198(1):328-34.

18: Iyengar R, Rich KA, Herberg JT, Premont RT, Codina J. Glucagon receptor-mediated activation of Gs is accompanied by subunit dissociation. J Biol Chem. 1988 Oct 25;263(30):15348-53.

19: Livingston JN, Einarsson K, Backman L, Ewerth S, Arner P. Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects. J Clin Invest. 1985 Feb;75(2):397-403.